Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of Dolby Laboratories, Inc. from 28 Sep 2018 to 26 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Dolby Laboratories, Inc. annual and quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 28 Sep 2018 to 26 Sep 2025.
  • Dolby Laboratories, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 27 Dec 2024 was $33,905,000.
  • Dolby Laboratories, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2025 was $215,609,000.
  • Dolby Laboratories, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was $240,214,000, a 227% decline from 2023.
  • Dolby Laboratories, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was $189,595,000.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)

Dolby Laboratories, Inc. Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $215,609,000 +$455,823,000 28 Sep 2024 26 Sep 2025 10-K 18 Nov 2025 2025 FY
2024 $240,214,000 -$429,809,000 -227% 30 Sep 2023 27 Sep 2024 10-K 18 Nov 2025 2025 FY
2023 $189,595,000 +$794,256,000 01 Oct 2022 29 Sep 2023 10-K 18 Nov 2025 2025 FY
2022 $604,661,000 -$757,714,000 -495% 25 Sep 2021 30 Sep 2022 10-K 19 Nov 2024 2024 FY
2021 $153,053,000 -$121,333,000 -44% 26 Sep 2020 24 Sep 2021 10-K 17 Nov 2023 2023 FY
2020 $274,386,000 +$394,043,000 28 Sep 2019 25 Sep 2020 10-K 18 Nov 2022 2022 FY
2019 $119,657,000 -$410,539,000 -141% 29 Sep 2018 27 Sep 2019 10-K 17 Nov 2021 2021 FY
2018 $290,882,000 30 Sep 2017 28 Sep 2018 10-K 16 Nov 2020 2020 FY

Dolby Laboratories, Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $33,905,000 +$143,213,000 28 Sep 2024 27 Dec 2024 10-Q 30 Jan 2025 2025 Q1
Q4 2023 $109,308,000 -$112,414,000 -3619% 30 Sep 2023 29 Dec 2023 10-Q 30 Jan 2025 2025 Q1
Q4 2022 $3,106,000 +$171,706,000 01 Oct 2022 30 Dec 2022 10-Q 02 Feb 2024 2024 Q1
Q4 2021 $168,600,000 -$208,046,000 -527% 25 Sep 2021 31 Dec 2021 10-Q 02 Feb 2023 2023 Q1
Q4 2020 $39,446,000 +$91,884,000 26 Sep 2020 25 Dec 2020 10-Q 04 Feb 2022 2022 Q1
Q4 2019 $52,438,000 28 Sep 2019 27 Dec 2019 10-Q 29 Jan 2021 2021 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.